E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acceleration of fracture healing |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Bones and nerves physological processes [G11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10016454 |
E.1.2 | Term | Femur fracture |
E.1.2 | System Organ Class | 10022117 - Injury, poisoning and procedural complications |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate the effect of AMG 785 compared to placebo on functional healing as measured by the timed-up-and-go test (TUG) over Weeks 6 through 20 in subjects with fresh unilateral low energy hip fractures. |
|
E.2.2 | Secondary objectives of the trial |
To investigate the effect of AMG 785 compared to placebo on:
(1) TUG value by visit
(2) Time to radiographic healing defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on anteroposterior (AP) & lateral (or oblique) radiographs
(3) Radiographic Union Scale for Hip (RUSH) score by visit
(4) Harris Hip Score
(5) Pain as a result of the hip fracture as assessed by the Visual Analog Scale (VAS) |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Dual energy X-ray Absorptiometry (DXA) and PK/PD sub-study, version dated 22 October 2009:
Approximately 40 subjects per arm (approximately 160 subjects in total) will be enrolled into this sub-study to undergo DXA scans of the lumbar spine and proximal femur and have blood drawn for
PK/PD analysis. This sub-study will evaluate the percent change from baseline on lumbar spine and hip BMD at Week 52. Blood samples will be used for assessment of AMG 785, sclerostin, and bone turnover markers P1NP and CTX.
The evaluation of the Dutch version of the Hip disability and Osteoarthritis Outcome Score (HOOS) as an outcomes instrument in a hip fracture population will be performed in the Netherlands.
|
|
E.3 | Principal inclusion criteria |
Adult women or men, age ≥ 55 to ≤ 95 years at randomization
Fresh unilateral low energy intertrochanteric or femoral neck fracture as the primary injury, confirmed by X-ray and in the opinion of the treating surgeon amenable to repair by internal fixation
Intertrochanteric fractures eligible for this study must have at least two displaced fragments
Internal fixation of the fracture with devices approved by local regulatory agency, performed no later than 7 days after injury for intertrochanteric or undisplaced femoral neck fractures and no later than 2 days after injury for displaced femoral neck fractures
• Intertrochanteric fracture: sliding hip screw or IM nail
• Femoral neck fracture: sliding hip screw or at least three cancellous screws
Pre- and postoperative care performed as defined in Appendix I
Subject or subject’s legally acceptable representative has provided informed
consent |
|
E.4 | Principal exclusion criteria |
Conditions that may affect the ability to perform functional or clinical
assessments required by the protocol, such as:
• Severe symptomatic osteoarthritis of the lower extremity
• Inability to independently rise from armchair or walk 200 meters before hip
fracture (use of unilateral assistive device or rolling walker is acceptable)
• Cognitive deficit, as defined by Mini-Mental Status Examination score < 22 at
time of randomization
• Symptomatic neurological conditions such as Parkinson’s disease or persistent
gross motor or sensory deficits such as hemiparesis or hemiplegia
• Presence of concomitant injuries such as rib fractures, wrist fractures, or acute
symptomatic vertebral fractures which severely impair the ability to rise from a
chair
• Associated extremity injuries including ipsilateral or contralateral fractures of the
foot, tibia or fibula, wrist, humerus, femoral shaft, femoral head or hip dislocation,
that may delay weight-bearing beyond one week after surgery
Use of bone grafts or bone substitutes at the time of fracture fixation
Head-injury, as defined by Glasgow Coma Scale <13 prior to randomization
Major polytrauma or significant axial trauma, with Injury Severity Score > 16
Pathological fracture or history of metabolic or bone disease (except
osteoporosis) that may interfere with the interpretation of the results, such as Paget’s disease, rheumatoid
arthritis, osteomalacia, osteopetrosis, ankylosing spondylitis, Cushing’s disease,
hyperprolactinemia
History of symptomatic spinal stenosis that has not been surgically corrected. If surgically corrected, the subject must be asymptomatic to be eligible for the study
History of facial nerve paralysis
Malignancy (except fully resected cutaneous basal cell or squamous cell
carcinoma, cervical carcinoma in situ) within the last 5 years
Severe asthma or severe chronic obstructive pulmonary disease or recent exacerbation
Myocardial infarction or unstable angina pectoris within the last 12 months
Current alcohol dependence
History of solid organ or bone marrow transplants
Per subject report, chart review or local laboratory result, evidence of currently abnormal values for the following:
• Elevated transaminases (a) Serum aspartate aminotransferase ≥ 2.0 x
upper limits of normal; (b) Serum alanine aminotransferase ≥ 2.0 x upper
limits of normal
• Significantly impaired renal function as determined by a derived creatinine
clearance of ≤ 30 mL/min using the Modification of Diet in Renal Disease
equation (Levey et al, 1999). The estimated glomerular filtration rate is
calculated as follows: estimated glomerular filtration rate (mL/min/1.73m2)
= 186 x [Serum creatinine (mg/dL)]-1.154 x [Age]-0.203 x [0.742 if subject is
female] x [1.210 if subject is black].
• Hypocalcemia or hypercalcemia, outside of 1.1 x the normal range set by the local laboratory
Known to have tested positive for human immunodeficiency virus, hepatitis C
virus, or hepatitis B surface antigen
- Use of the following agents affecting bone metabolism
• Within the past 12 months: parathyroid hormone, strontium, fluoride (for osteoporosis)
• Within the past 6 months: IV bisphosphonates, denosumab, odanacatib (MK-0822)
• Within the past 3 months: calcitonin, tibolone, cinacalcet, systemic glucocorticosteroids (≥ 5 mg prednisone equivalent per day for more than 10 days)
Bone Morphogenetic Protein (BMP)-2 or BMP-7 at the time of definitive fracture fixation
Subjects to be enrolled in DXA sub-study may not have had previous
instrumentation with implants (ie, nails, screws, pins, plates) to either hip or lower
spine
General
• Currently enrolled in another investigational device, drug, or biologics
product study, or less than 30 days since ending another investigational
device, drug, or biologics product study(s), or receiving other
investigational agent(s).
• Previous enrollment in an AMG 785 clinical study
• Females of childbearing potential: Subject refuses to use an effective
contraception (or true abstinence) during treatment with study product and for an
additional 3 months after the end of treatment with study product (ie, 3 months
after the week 12 study visit)
Subject is pregnant (eg, positive human chorionic gonadotropin test) or breast
feeding, or planning to become pregnant during treatment with study product or
within 3 months after the end of treatment with study product (ie, 3 months after
the Week 12 study visit)
Subject has known sensitivity or intolerance to any of the products to be
administered (calcium supplements, vitamin D products, or mammalian cell
derived products) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the difference in mean TUG (timed up-and-go) over Weeks 6 through Week 20 between the AMG 785 and placebo groups.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
To investigate the effect of AMG 785 compared to placebo on:
• TUG value by visit
• Time to radiographic healing, defined as effacement of the fracture lines by newly formed bone along the cortices and within the trabecular bone on AP & lateral (or oblique) radiographs
• RUSH score by visit
• Harris Hip Score by visit
• Pain score as measured by VAS by visit
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Weeks 2,6,12,16,20,24 and 36 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 51 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
European Union |
Argentina |
Australia |
Canada |
Hong Kong |
India |
New Zealand |
Switzerland |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study (EOS) is defined as the date the last eligible subject completes the final
study visit at Week 52. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |